Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4 Recap with Dr. Steven Ferrucci
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4.
10 Mai 20225min
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3 Recap with Dr. Rishi Singh
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3.
10 Mai 20224min
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2 Recap with Dr. Steven Ferrucci
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2.
10 Mai 20225min
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1 Recap with Dr. Rishi Singh
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1.
10 Mai 20224min
Multidisciplinary Strategies to Reduce the Burden of Ocular Toxicities in Myeloma With Drs. Sagar Lonial and Asim V. Farooq
In this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
31 Jan 202215min
Managing Ocular Toxicities in Patients on Multiple Myeloma Therapy With Drs. Sagar Lonial and Asim V. Farooq
In this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
31 Jan 202216min
Frequency and Identification of Ocular Toxicities Associated With Myeloma Therapy With Drs. Sagar Lonial and Bennie Jeng
In this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
31 Jan 202213min
Mechanisms Underlying Ocular Toxicities in Cancer Therapy With Drs. Bennie Jeng and Sagar Lonial
In this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
31 Jan 202214min
